Pérez-Areales Francisco Javier, Betari Nibal, Viayna Antonio, Pont Caterina, Espargaró Alba, Bartolini Manuela, De Simone Angela, Rinaldi Alvarenga José Fernando, Pérez Belén, Sabate Raimon, Lamuela-Raventós Rosa Maria, Andrisano Vincenza, Luque Francisco Javier, Muñoz-Torrero Diego
Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), Faculty of Pharmacy & Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.
Institute of Biomedicine (IBUB), University of Barcelona, E-08028 Barcelona, Spain.
Future Med Chem. 2017 Jun;9(10):965-981. doi: 10.4155/fmc-2017-0049. Epub 2017 Jun 20.
Simultaneous modulation of several key targets of the pathological network of Alzheimer's disease (AD) is being increasingly pursued as a promising option to fill the critical gap of efficacious drugs against this condition.
MATERIALS & METHODS: A short series of compounds purported to hit multiple targets of relevance in AD has been designed, on the basis of their distinct basicities estimated from high-level quantum mechanical computations, synthesized, and subjected to assays of inhibition of cholinesterases, BACE-1, and Aβ42 and tau aggregation, of antioxidant activity, and of brain permeation.
Using, as a template, a lead rhein-huprine hybrid with an interesting multitarget profile, we have developed second-generation compounds, designed by the modification of the huprine aromatic ring. Replacement by [1,8]-naphthyridine or thieno[3,2-e]pyridine systems resulted in decreased, although still potent, acetylcholinesterase or BACE-1 inhibitory activities, which are more balanced relative to their Aβ42 and tau antiaggregating and antioxidant activities.
Second-generation naphthyridine- and thienopyridine-based rhein-huprine hybrids emerge as interesting brain permeable compounds that hit several crucial pathogenic factors of AD.
同时调节阿尔茨海默病(AD)病理网络的几个关键靶点,正日益被视为一种有前景的选择,以填补针对这种疾病有效药物的关键缺口。
基于从高水平量子力学计算估计的不同碱性,设计了一系列据称能作用于AD多个相关靶点的化合物,进行合成,并对其进行胆碱酯酶、β-分泌酶-1(BACE-1)、Aβ42和tau蛋白聚集抑制试验、抗氧化活性试验以及脑渗透性试验。
以具有有趣多靶点特征的先导化合物大黄酸-石杉碱杂合物为模板,通过修饰石杉碱芳香环设计了第二代化合物。用[1,8]-萘啶或噻吩并[3,2-e]吡啶系统取代,导致乙酰胆碱酯酶或BACE-1抑制活性降低,尽管仍然有效,但其相对于Aβ42和tau蛋白抗聚集及抗氧化活性更为平衡。
基于萘啶和噻吩并吡啶的第二代大黄酸-石杉碱杂合物是有前景的脑渗透性化合物,可作用于AD的几个关键致病因素。